Shares of Moleculin Biotech cratered 29.9% to $0.54 on September 21, 2026, after the clinical-stage drugmaker disclosed that Nasdaq has moved to kick it off the exchange — a blow that strips away one of the last pillars of legitimacy for a company whose stock has spent weeks trading well below a dollar. Moleculin Biotech Stares Down Nasdaq Eviction — Is There Any Road Back for a Stock That Has Already Used Its Last Lifeline?
Shares plunged 29.9% to $0.54 on September 21, 2026, after Moleculin Biotech disclosed that Nasdaq has moved to delist the clinical-stage cancer drugmaker — and, critically, denied it the usual six-month grace period to fix the problem. With the broader market trading higher the same day, the selloff is entirely about one company running out of options.
A Repeat Offender That Burned Its Get-Out-of-Jail Card
Moleculin's stock closed below Nasdaq's $1.00 minimum price for 30 straight trading days, from July 31 through September 11, 2026, violating the exchange's listing rules. Normally, a company gets 180 days to push its price back above the threshold. But Nasdaq denied that cushion because Moleculin had already executed a 1-for-25 reverse stock split — essentially merging every 25 old shares into one new share to inflate the price — that took effect December 1, 2025.
Before that, it did a 1-for-15 reverse split in March 2024 for the same reason. The pattern is clear: the company keeps shrinking its share count to prop up its price, and the price keeps falling back below a dollar.
The Stock Has Lost 92% in a Year — and the Damage May Not Be Over
MBRX trades down roughly 92% from its 52-week high of $15.75.
Delisting would severely hurt the company's ability to raise capital through stock sales, drive away institutional investors, and reduce the number of brokers willing to trade the shares — a death spiral for a company that generates no revenue and relies on the public markets to fund its drug trials.
A Hearing Buys Time, but Not a Plan
Moleculin says it will request a hearing before a Nasdaq panel, which would temporarily keep the stock trading on the exchange while the case is reviewed.
Hearings typically follow a request by roughly 30–45 days. But the company's filing does not disclose a hearing date and does not disclose any plan to regain compliance — the two things investors most need to see.
No Revenue, No Margin for Error
Moleculin has no revenue, mounting losses, and is focused on developing experimental cancer treatments for highly resistant tumors. Without a Nasdaq listing, the fundraising pipeline that keeps the lights on becomes far harder to access. The hearing is the last stand — and the company hasn't yet told investors what its argument will be.